Sign inJoin waitlistJoin the waitlist

Timothy Yap

VP, Head of Clinical Development · University of Texas M D Anderson Cancer Center

Credentials: · · · ·

History

University of Texas M D Anderson Cancer Center
Present
University of Texas M D Anderson Cancer Center
Present
Head of Clinical Development · University of Texas M D Anderson Cancer Center
Present

Royal Marsden Hospital
2010–2013
Royal Marsden Hospital and the Institute of Cancer Research
2006–2010
Medical Oncology
2005–2006
Oxford University Hospitals
2003–2005
St. Mary’s Hospital
2002–2003
Doctor of Medicine
1998–2002

Research

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers
New England Journal of Medicine · 2009 · 2,967 citations
State-of-the-art strategies for targeting the DNA damage response in cancer
Review · Nature Reviews Clinical Oncology · 2019 · Last of 4 authors · Corresponding · 926 citations
Targeting the PI3K pathway in cancer: are we making headway?
Review · Nature Reviews Clinical Oncology · 2018 · 844 citations

Funda Meric-Bernstam
58 papers
David Hong
37 papers
Sarina Piha-Paul
36 papers
Aung Naing
34 papers
Siqing Fu
33 papers
Jordi Ahnert
32 papers · 6 as a fellow
Apostolia Tsimberidou
24 papers
DK
Daniel Karp
24 papers
Ecaterina Dumbrava
24 papers
Vivek Subbiah
22 papers
Shubham Pant
17 papers
FJ
Filip Janku
12 papers

Grants

Transcriptomic Mechanisms Underlying the Immune Modulating Function and Therapeutic Efficacy of PARP Inhibitors
National Cancer Institute · R01
Contact PI · $1.8M · University of Tx Md Anderson Can Ctr
2021–2026

Clinical trials

EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors
Principal investigator · Recruiting · Phase 1, Phase 2
Eisbach Bio GmbH
2024–2027
Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers
Principal investigator · Terminated · Phase 1
M.D. Anderson Cancer Center
2024–2026
Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET)
Principal investigator · Recruiting · Phase 2
M.D. Anderson Cancer Center
2023–2029
Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial
Principal investigator · Recruiting · Phase 2
National Cancer Institute (NCI)
2022–2027